For the second quarter cumulative period of the 2026 fiscal year (2026\/1\/1-2026\/6\/30), non-operating income of 2000 ten thousand yen and non-operating expenses of 1300 ten thousand yen were recognized. The primary driver is gains from foreign exchange remeasurement of foreign-currency assets, including gains from currency fluctuations. Interest expenses and other costs were also recorded for the period. The impact on performance is described in the Earnings Report for the fiscal year ending December 2026 published on August 7, 2026 (Japanese accounting standards, non-consolidated).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncoris Biopharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4588-20260807-02.pdf","jir_short_summary":"For the second quarter cumulative period of the 2026 fiscal year (2026\/1\/1-2026\/6\/30), non-operating income of 2000 ten thousand yen and non-operating expenses of 1300 ten thousand yen were recognized. The primary driver is gains from foreign exchange remeasurement of foreign-currency assets, including gains from currency fluctuations. Interest expenses and other costs were also recorded for the period. The impact on performance is described in the Earnings Report for the fiscal year ending December 2026 published on August 7, 2026 (Japanese accounting standards, non-consolidated).","jir_summary":"### Overview\nThis report specifies the recognition of non-operating income and non-operating expenses for the second quarter cumulative period of the 2026 fiscal year (January 1, 2026 to June 30, 2026). The main non-operating income comes from foreign exchange gains due to remeasurement of foreign-currency assets, totaling 20\u767e\u4e07\u5186 (with an additional 8\u767e\u4e07\u5186 recognized in Q2-Q4). Non-operating expenses total 13\u767e\u4e07\u5186 (with an additional 8\u767e\u4e07\u5186 recognized in Q2-Q4), centered on interest expenses. The impact on performance is described in the separately published Earnings Summary.\n\n### Future impact and notes\nThe impact on performance from these non-operating income and expenses is explained in the August 7, 2026 release of the Earnings Summary for the 2026 December interim period (Japanese standards, non-consolidated). These are temporary factors such as foreign exchange gains, and their effect on full-year performance follows what is stated in that Earnings Summary. Specific amounts and future outlook are not included in this document; any questions should refer to the Earnings Summary supplementary information.","jir_financial_highlights":"Non-operating income: 20\u767e\u4e07\u5186 (Breakdown: FX gains of 17\u767e\u4e07\u5186, interest income 3\u767e\u4e07\u5186, additional recognition of 8\u767e\u4e07\u5186 in Q2-Q4)\nNon-operating expenses: 13\u767e\u4e07\u5186 (Breakdown: interest expenses 8\u767e\u4e07\u5186, stock-based compensation amortization with performance restrictions 2\u767e\u4e07\u5186, additional recognition of 8\u767e\u4e07\u5186 in Q2-Q4)\nImpact: Unknown (Impact on performance described in the Earnings Summary published on August 7, 2026)","jir_category":"","jir_hashtags":"#OncorisBiopharma, #Non-operatingIncome, #Non-operatingExpense","jir_key_figures":"Non-operating income: 20\u767e\u4e07\u5186\nNon-operating expenses: 13\u767e\u4e07\u5186\nQ2-Q4 additional recognition: Non-operating income 8\u767e\u4e07\u5186 \/ Non-operating expenses 8\u767e\u4e07\u5186","jir_meta_title":"\u3010Oncoris Biopharma\u3011Notice of recognition of non-operating income and expenses | August 2026","jir_meta_description":"Oncoris Biopharma announces non-operating income of 20\u767e\u4e07\u5186 and non-operating expenses of 13\u767e\u4e07\u5186 for the second quarter cumulative period of 2026. Explains contributing factors including foreign exchange gains and breakdown of mid-period additions.","jir_og_title":"\u3010Oncoris Biopharma\u3011Notice of recognition of non-operating income and expenses","jir_og_description":"Disclosure of non-operating income and expenses for the second quarter of 2026. Summarizes factors including foreign exchange gains and references the Earnings Summary for performance impact.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-99682","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n